Replies to post #693439 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

IMO, the following trial sponsored by Oncovir can provide us with some answers on the possibilities in the near future.

Our group has initiated a novel intratumoral in situ strategy which uses the patient’s tumor as the antigen source. We expect this approach to convert the prostate tumor into a favorable immune ecosystem and improve the anti-tumor immune response. We are currently testing this strategy in a Phase 1 dose-escalation study designed to define a safe dose and schedule of preoperative intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) before radical prostatectomy for patients with intermediate and high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP) (NCT03262103). Poly-ICLC is a synthetic agonist that activates TLR3, resulting in upregulation of innate immune genes that also activate adaptive immune responses. Poly-ICLC injections generate a broad immune response in humans that will aid generation of tumor suppressive immune milieu280

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
https://clinicaltrials.gov/study/NCT03262103